問卷

TPIDB > Search Result

Search Result

篩選

List

106Cases

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

2024-10-01 - 2029-09-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2031-05-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-12-17 - 2030-08-23

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-05-26 - 2031-01-28

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-06-30 - 2032-05-01

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-07-15 - 2029-11-13

Phase II/III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-08-01 - 2035-08-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-08-18 - 2030-06-30

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites